SG11202113212YA - Tetracyclic compounds as cdc7 inhibitors - Google Patents
Tetracyclic compounds as cdc7 inhibitorsInfo
- Publication number
- SG11202113212YA SG11202113212YA SG11202113212YA SG11202113212YA SG11202113212YA SG 11202113212Y A SG11202113212Y A SG 11202113212YA SG 11202113212Y A SG11202113212Y A SG 11202113212YA SG 11202113212Y A SG11202113212Y A SG 11202113212YA SG 11202113212Y A SG11202113212Y A SG 11202113212YA
- Authority
- SG
- Singapore
- Prior art keywords
- tetracyclic compounds
- cdc7 inhibitors
- cdc7
- inhibitors
- tetracyclic
- Prior art date
Links
- 101150065030 cdc7 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910464384 | 2019-05-30 | ||
| CN201910491339 | 2019-06-06 | ||
| CN201911128459 | 2019-11-18 | ||
| PCT/CN2020/093480 WO2020239107A1 (fr) | 2019-05-30 | 2020-05-29 | Composés tétracycliques agissant en tant qu'inhibiteurs de cdc7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113212YA true SG11202113212YA (en) | 2021-12-30 |
Family
ID=73553516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113212YA SG11202113212YA (en) | 2019-05-30 | 2020-05-29 | Tetracyclic compounds as cdc7 inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220235068A1 (fr) |
| EP (1) | EP3978501A4 (fr) |
| JP (1) | JP2022534316A (fr) |
| KR (1) | KR20220027883A (fr) |
| CN (2) | CN113874379B (fr) |
| AU (1) | AU2020281411A1 (fr) |
| BR (1) | BR112021023886A2 (fr) |
| CA (1) | CA3142202A1 (fr) |
| IL (1) | IL288472A (fr) |
| MX (1) | MX2021014629A (fr) |
| SG (1) | SG11202113212YA (fr) |
| WO (1) | WO2020239107A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114127077B (zh) * | 2019-08-20 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 用作Cdc7抑制剂的四并环类化合物 |
| JP2023551134A (ja) * | 2020-11-30 | 2023-12-07 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Ｃｄｃ７阻害剤としての塩及びその結晶形 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0407544A (pt) * | 2003-02-17 | 2006-02-14 | Pharmacia Italia Spa | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem |
| EP1621539A1 (fr) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases |
| EA020724B1 (ru) * | 2010-02-17 | 2015-01-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение, лекарственное средство, включающее его, и способы его применения |
| CN108779126B (zh) * | 2016-03-28 | 2021-07-16 | 武田药品工业株式会社 | 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3，2-d]嘧啶-4(3h)-酮半水合物的结晶形式 |
| JP2020508675A (ja) * | 2017-03-01 | 2020-03-26 | 武田薬品工業株式会社 | Ｃｄｃ７阻害剤の効果を予測する方法 |
-
2020
- 2020-05-29 SG SG11202113212YA patent/SG11202113212YA/en unknown
- 2020-05-29 AU AU2020281411A patent/AU2020281411A1/en not_active Abandoned
- 2020-05-29 CA CA3142202A patent/CA3142202A1/fr active Pending
- 2020-05-29 MX MX2021014629A patent/MX2021014629A/es unknown
- 2020-05-29 CN CN202080039204.XA patent/CN113874379B/zh active Active
- 2020-05-29 WO PCT/CN2020/093480 patent/WO2020239107A1/fr unknown
- 2020-05-29 KR KR1020217043231A patent/KR20220027883A/ko unknown
- 2020-05-29 JP JP2021571374A patent/JP2022534316A/ja not_active Withdrawn
- 2020-05-29 CN CN202310266535.2A patent/CN116425770A/zh active Pending
- 2020-05-29 BR BR112021023886A patent/BR112021023886A2/pt unknown
- 2020-05-29 US US17/595,869 patent/US20220235068A1/en active Pending
- 2020-05-29 EP EP20813107.8A patent/EP3978501A4/fr not_active Withdrawn
-
2021
- 2021-11-28 IL IL288472A patent/IL288472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022534316A (ja) | 2022-07-28 |
| EP3978501A4 (fr) | 2023-05-24 |
| EP3978501A1 (fr) | 2022-04-06 |
| BR112021023886A2 (pt) | 2022-01-18 |
| US20220235068A1 (en) | 2022-07-28 |
| MX2021014629A (es) | 2022-02-23 |
| AU2020281411A1 (en) | 2022-01-06 |
| KR20220027883A (ko) | 2022-03-08 |
| CN113874379A (zh) | 2021-12-31 |
| CN113874379B (zh) | 2023-03-31 |
| CA3142202A1 (fr) | 2020-12-03 |
| CN116425770A (zh) | 2023-07-14 |
| WO2020239107A1 (fr) | 2020-12-03 |
| IL288472A (en) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275089A (en) | Polycyclic substances as allosteric SHP2 inhibitors | |
| IL268030B (en) | Bicyclics as allosteric shp2 inhibitors | |
| ZA202207722B (en) | Substituted tricyclic compounds | |
| ZA202206253B (en) | Substituted tricyclic compounds | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL290087A (en) | inhibitory substances | |
| GB201819126D0 (en) | Inhibitor compounds | |
| EP3997097C0 (fr) | Dérivés spirocycliques macrocycliques en tant qu'inhibiteurs de mcl-1 | |
| GB201914860D0 (en) | Inhibitor compounds | |
| EP3844166C0 (fr) | Macrocycles substitués utiles en tant qu'inhibiteurs de kinase | |
| IL288987A (en) | New heterocyclic compounds | |
| IL288472A (en) | Tetracyclic compounds as cdc7 inhibitors | |
| IL287813A (en) | tricyclic compounds | |
| IL272507A (en) | Tricyclic compounds as histone methyltransferase inhibitors | |
| SG11202110808SA (en) | Organic compounds | |
| EP3641756A4 (fr) | Composés tricycliques utilisés comme inhibiteurs du cyp1 | |
| GB201905328D0 (en) | Inhibitor compounds | |
| EP4006036A4 (fr) | Composé tétracyclique utilisé en tant qu'inhibiteur de cdc7 | |
| GB201919213D0 (en) | Dihydrocyclopenta-Isoquinoline-Sulfanamide derivatives compounds | |
| IL292095A (en) | Thianopyrimidones as trpa1 inhibitors |